Share on

Latin America Preimplantation Genetic Testing Market Research Report - Segmented By Procedure Type, Technology, Products & Services, Application, End User & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2022 to 2027)

Published: March, 2023
ID: 6676
Pages: 145
Formats: report pdf report excel report power bi report ppt

Latin America Preimplantation Genetic Testing Market Size (2022 to 2027)

The size of the preimplantation genetic testing market in Latin America is anticipated to be worth USD 70.90 million by 2027 from USD 38.40 million in 2022, growing at a CAGR of 13.05% from 2022 to 2027.

Technological improvements in genetic analysis and the increased risk of chromosomal abnormalities with rising maternal age are driving market expansion. In addition, factors such as male and female infertility are fuelling the market’s growth rate in Latin America. Before implantation, preimplantation genetic testing is undertaken to aid in detecting congenital abnormalities in the embryos. In addition, preimplantation genetic testing examines the genetic profile of embryos, allowing for selective pregnancy termination to be avoided. The growth of the Latin American preimplantation genetic testing market is further driven by the growing population suffering from genetic disorders becoming aware of the benefits of preimplantation genetic testing. Furthermore, the rising occurrence of infertility is expected to boost the growth of Latin American preimplantation genetic testing.

The preimplantation genetic testing market in Latin America is expected to be propelled by advances in medical understanding, and technologically enhanced genetic devices become available. Furthermore, a favorable response from various regulatory agencies to genetic testing and the potential for having healthier offspring are significant benefits. So, again, more tech firms are projected to invest in testing. Therefore, the market is expected to develop significantly owing to the increasing availability of medical knowledge and the predominance of technologically improved genetic devices.

On the other hand, effective embryo development and various PGD applications, such as resolving infertility and chromosomal and genetic abnormalities, are key influencing factors. All these elements, taken together, generate the potential for market expansion, while some impede market growth. However, during the forecast period, each component will have a distinct impact on the market. The key factor impeding market expansion is ethical acceptability and judicial controls by public bodies, which prevent the adoption rate of PGT services. In addition, a few clinicians and researchers have questioned the efficacy of these techniques. However, the market is restrained by costs associated with preimplantation genetic testing and adverse government laws.

This research report on the Latin America preimplantation genetic testing market has been segmented and sub-segmented into the following categories:

By Procedure Type:

  • Genetic Diagnosis
  • Genetic Screening

By Technology:

  • NGS
  • PCR
  • FISH
  • CGH
  • SNP

By Products & Services:

  • Reagents And Consumables
  • Instruments
  • Software And Services

By Application:

  • Structural Chromosomal Abnormalities
  • Single Gene Disorders
  • X-Linked Disorders
  • HLA Typing
  • Gender Identification

By End User:

  • Fertility Clinics
  • Hospitals
  • Research Laboratories

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, Latin America captured a moderate share of the worldwide market in 2021. However, the Latin American market is anticipated to register a notable CAGR during the forecast period. The growing awareness of preimplantation genetic testing among patients with genetic disorders is propelling the demand for preimplantation genetic testing. Furthermore, the demand for preimplantation genetic testing and screening processes is linked to the rise in the incidence of a single gene, mitochondrial, and other gene-related illnesses. In addition, PGT is used in IVF cycles for women with many losses or whose most recent pregnancy had a chromosomal issue.

The Mexico preimplantation genetic testing market is anticipated to rise rapidly during the forecast period owing to more popular methods of detecting congenital disabilities in youngsters. The procedure is based on in vitro fertilization before pregnancy. However, the process is highly recommended in clinical practice, especially in cases where both parents have a genetic abnormality.

The Brazil preimplantation genetic testing market is expected to grow significantly over the forecast period. The rising demand for genetic testing and increased knowledge of genetics, big data, and AI technologies are prospective growth drivers for the preimplantation genetic testing industry.

The Argentina preimplantation genetic testing market is estimated to capture a considerable share of the Latin American market during the forecast period owing to the growing medical tourism. Increased awareness of preimplantation genetic testing would provide good potential for market growth. In addition, IVF therapy in combination with PGT procedures is advised for many patients with infertility and poor fecundity, which is predicted to accelerate growth. Furthermore, governmental and private authorities support reproductive health through initiatives that fuel the preimplantation genetic testing market.

KEY MARKET PLAYERS

Prominent companies dominating the Latin America Preimplantation Genetic Testing Market profiled in the report are Rubicon Genomics, Inc., Agilent Technologies, Inc., Abbott Laboratories, PerkinElmer, Inc., & SciGene Corporation, Yukon Genomics, CooperSurgical, Thermo Fisher Scientific, Inc, Illumina, Inc. and Natera.

Please wait. . . . Your request is being processed

FAQ's

What is the growth rate of the Latin America preimplantation genetic testing market?

The Latin America preimplantation genetic testing market is projected to witness a CAGR of 13.05% between 2022 to 2027.

What are the factors driving the growth of the Latin America preimplantation genetic testing market?

The rising awareness about genetic testing, rising infertility rates, increasing demand for IVF services, and increasing government support for IVF treatments are propelling the Latin American preimplantation genetic testing market.

Who are the key players in the Latin America preimplantation genetic testing market?

CooperSurgical, Inc., Illumina, Inc., Natera, Inc., and PerkinElmer, Inc. are some of the noteworthy companies in the Latin American preimplantation genetic testing market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample